Reference - Detail
| RRC ID | 68643 |
|---|---|
| Author | Hebishima T, Matsumoto Y, Watanabe G, Soma G, Kohchi C, Taya K, Hayashi Y, Hirota Y. |
| Title | Oral administration of immunopotentiator from Pantoea agglomerans 1 (IP-PA1) improves the survival of B16 melanoma-inoculated model mice. |
| Journal | Exp Anim |
| Abstract |
To investigate the usefulness of the immunopotentiator from Pantoea agglomerans 1 (IP-PA1) as a supportive drug in melanoma therapy, we analyzed the immunological effects of IP-PA1 on melanoma-inoculated model mice. Oral administration of IP-PA1 increased the serum levels of tumor necrosis factor (TNF)-α at 2 h after the administration and interferon (IFN)-γ and IL-12 at 12 h after the administration in naïve BALB/cCrSlc mice as evaluated by ELISA. IP-PA1 did not affect the proliferation of melanoma cells directly determined by the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay. Combinatory treatment of IP-PA1 with doxorubicin for 9 days increased the serum levels of IFN-γ and IL-12 by 71.0 and 15.3%, respectively, compared to the treatment of doxorubicin alone in melanoma-bearing C57BL/6NCrSlc mice as evaluated by ELISA. It also increased the proportion of natural killer (NK) cells and the ratio of CD4(+) to CD8(+) T cells in the spleen from 6.1 ± 0.3 to 7.4 ± 0.5% and from 1.25 ± 0.03 to 1.38 ± 0.04, respectively, compared to the treatment of doxorubicin alone as analyzed by flow cytometry. The mean survival period of melanoma-bearing, doxorubicin treated mice was prolonged from 31.4 ± 7.1 to 35.3 ± 8.4, 51.1 ± 5.4, and 45.0 ± 8.4 days by combinatory treatment of IP-PA1 at the daily doses of 0.1, 0.5, and 1 mg/kg, respectively. In conclusion, the results of the present study suggest the usefulness of IP-PA1 as a supportive drug in melanoma therapy. |
| Volume | 60(2) |
| Pages | 101-9 |
| Published | 2011-1-1 |
| DOI | 10.1538/expanim.60.101 |
| PII | JST.JSTAGE/expanim/60.101 |
| PMID | 21512265 |
| MeSH | Adjuvants, Immunologic / administration & dosage Adjuvants, Immunologic / therapeutic use* Animals CD4-CD8 Ratio Cell Proliferation / drug effects Doxorubicin / therapeutic use* Female Flow Cytometry Interferon-gamma / blood Interleukin-12 / blood Killer Cells, Natural / immunology Lipopolysaccharides / administration & dosage Lipopolysaccharides / therapeutic use* Melanoma, Experimental / drug therapy* Melanoma, Experimental / immunology Melanoma, Experimental / mortality Mice Mice, Inbred C57BL Pantoea / chemistry* Skin Neoplasms / drug therapy* Skin Neoplasms / immunology Skin Neoplasms / mortality Spleen / immunology Tumor Necrosis Factor-alpha / blood |
| IF | 1.574 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | Patent(IFI CLAIMS) |
| Total number of mentions | 17 |
| Altmetric score changes over past 6months | 0.2 |
| Resource | |
| Human and Animal Cells | B16 melanoma 4A5(RCB0557) |